Oscar Health, Inc. (OSCR) continued its upward trajectory, soaring 5.17% in pre-market trading on Thursday, building on the previous day's 5.05% gain. The surge comes in the wake of the health insurance technology company's exceptional first-quarter 2025 financial results, which significantly outperformed analyst expectations across key metrics.
The company reported a robust earnings per share (EPS) of $0.92, comfortably surpassing the consensus estimate range of $0.79-$0.83. Oscar Health's revenue for the quarter reached an impressive $3.05 billion, marking a substantial 42% year-over-year increase and exceeding the expected $2.86-$2.87 billion. This strong top-line growth was primarily driven by higher membership numbers. Furthermore, the company demonstrated improved operational efficiency with an adjusted EBITDA of $328.8 million, significantly outperforming the analyst estimate of $280.8 million.
Oscar Health's ability to translate growth into profitability was evident in its impressive net income of $275.3 million. The company's medical loss ratio stood at 75.4%, while the SG&A expense ratio improved to 15.8%, down from 18.4% in the same quarter last year, indicating enhanced cost management. Adding to investor optimism, Oscar Health reaffirmed its full-year 2025 guidance across all metrics, further solidifying confidence in the company's future prospects within the evolving healthcare technology landscape. The strong financial performance and positive outlook have clearly resonated with investors, driving the stock's continued momentum in pre-market trading.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。